Specialized Medical Company (TADAWUL:4019)

TADAWUL:4019 Income Statement

Financials in millions SAR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	1,445	1,440	1,368	1,209	1,053
Revenue Growth (YoY)	19.59%	5.24%	13.18%	14.77%	-
Cost of Revenue	1,066	1,055	1,019	930	824.89
Gross Profit	379.21	384.85	348.96	278.66	228.24
Selling, General & Admin	169.61	154.55	134.38	150.91	159.04
Operating Expenses	169.61	154.55	134.38	150.91	159.04
Operating Income	209.61	230.3	214.58	127.75	69.2
Interest Expense	-44.91	-44.98	-48.46	-29.82	-18.89
Other Non Operating Income (Expenses)	11.09	10.62	8.52	9.13	8.92
EBT Excluding Unusual Items	175.8	195.95	174.65	107.05	59.24
Gain (Loss) on Sale of Assets	-2.29	-2.29	0.05	0.06	0.05
Pretax Income	173.5	193.66	174.7	107.12	59.29
Income Tax Expense	7.85	8.44	6	4.15	3.32
Net Income	165.65	185.22	168.7	102.96	55.97
Net Income to Common	165.65	185.22	168.7	102.96	55.97
Net Income Growth	60.89%	9.79%	63.84%	83.97%	-
Shares Outstanding (Basic)	250	250	9	9	9
Shares Outstanding (Diluted)	250	250	9	9	9
Shares Change (YoY)	2841.18%	2841.18%	-	-	-
EPS (Basic)	0.66	0.74	19.85	12.11	6.58
EPS (Diluted)	0.66	0.74	19.85	12.11	6.58
EPS Growth	-94.53%	-96.27%	63.84%	83.97%	-
Free Cash Flow	362.29	289.52	160.53	116.6	-159.38
Free Cash Flow Per Share	1.45	1.16	18.89	13.72	-18.75
Gross Margin	26.24%	26.73%	25.51%	23.05%	21.67%
Operating Margin	14.50%	16.00%	15.69%	10.57%	6.57%
Profit Margin	11.46%	12.87%	12.33%	8.52%	5.31%
Free Cash Flow Margin	25.06%	20.11%	11.73%	9.65%	-15.13%
EBITDA	269.1	288.77	273.08	202.59	141.55
EBITDA Margin	18.62%	20.06%	19.96%	16.76%	13.44%
D&A For EBITDA	59.49	58.47	58.49	74.85	72.35
EBIT	209.61	230.3	214.58	127.75	69.2
EBIT Margin	14.50%	16.00%	15.69%	10.57%	6.57%
Effective Tax Rate	4.52%	4.36%	3.44%	3.88%	5.60%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.